EUVIMEDEUVIMED entdecken
Übersichtsarbeit

New therapies for primary biliary cholangitis

Aalam Sohal, Mariam Alamgir, Kris V Kowdley

Hepatology International · 2026-06 · 20 (3) · 587-595

DOI: 10.1007/s12072-026-11088-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hepatology International, online erschienen am 08.05.2026. Verfasst von Aalam Sohal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Liver Institute Northwest, 3216 NE 45th Pl Suite 100, Seattle, WA, 98105, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary. Die Arbeit nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Primary Biliary Cholangitis (PBC) is a cholestatic autoimmune liver disease of small bile ducts. Ursodeoxycholic acid (UDCA) was approved as a first line therapeutic option for PBC in 1997. It was later noted that 40% of patients with PBC are either non-responders or intolerant to UDCA. In 2016, obeticholic acid (OCA) was approved as a second-line therapy for PBC. However, due to the side effects associated with OCA and the FDA restricting its use in patients with cirrhosis, there was a need for additional therapies. AIMS: This review summarizes the current literature regarding the new and emerging therapies for patients with PBC. KEY FINDINGS: In 2024, two new therapies, elafibranor and seladelpar were approved as a second-line treatment for PBC. In 2025 OCA was withdrawn from the market. Multiple additional therapies targeting biochemical remission are under investigation. Furthermore, a new class of medication, ileal bile acid transporter inhibitors (IBAT inhibitors), is being studied for pruritus among these patients. CONCLUSION: The therapeutic landscape for PBC has been rapidly evolving with the discovery of second-line agents. Ongoing trials studying biochemical response, symptom control and long-term clinical outcomes among patients with PBC will be beneficial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Cirrhosis, BiliaryHumansChenodeoxycholic AcidUrsodeoxycholic AcidCholagogues and CholereticsPropionatesIsoxazolesMethylaminesThiazepinesChalcones

Stichwörter der Autor:innen

ElafibranorEmerging therapiesIBAT inhibitorsNew therapiesPBCPemafibrateSaroglitazar

Substanzen

Chenodeoxycholic Acidobeticholic acidUrsodeoxycholic Acid3-((((3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino…Cholagogues and CholereticselifibranorPropionatesIsoxazolesMethylaminesThiazepines

Autor:innen und Institutionen

  • Liver Institute Northwest, 3216 NE 45th Pl Suite 100, Seattle, WA, 98105, USA.
  • Creighton University, Phoenix, AZ, USA.
  • Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
  • Liver Institute Northwest, 3216 NE 45th Pl Suite 100, Seattle, WA, 98105, USA. kkowdley@liverinstitutenw.org.
  • Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA. kkowdley@liverinstitutenw.org.

Zitieren

APA

Sohal, A., Alamgir, M., & Kowdley, K. V. (2026). New therapies for primary biliary cholangitis. Hepatology International, 20(3), 587-595. https://doi.org/10.1007/s12072-026-11088-2

Vancouver

Sohal A, Alamgir M, Kowdley KV. New therapies for primary biliary cholangitis. Hepatology International. 2026;20(3):587-595. doi:10.1007/s12072-026-11088-2

BibTeX
@article{Sohal2026,
  author = {Sohal, Aalam and Alamgir, Mariam and Kowdley, Kris V},
  title = {New therapies for primary biliary cholangitis},
  journal = {Hepatology International},
  year = {2026},
  volume = {20},
  number = {3},
  pages = {587--595},
  doi = {10.1007/s12072-026-11088-2}
}
Kostenlos starten →